Clinical Trial

Real-world Secukinumab Outcomes in Canadian HS Patients

Study acronym: HS-RISE
Recruiting
View on ClinicalTrials.gov →
Summary
The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.
Protocol Amendment History 1 change
notable Trial sites expanded: 7 -> 11 locations 2026-04-16
Trial Details
NCT Number NCT07282015
Lead Sponsor Novartis Pharmaceuticals
Conditions Hidradenitis Suppurativa
Enrollment 142 participants
Start Date 2025-12-12
Primary Completion 2028-02-11 (estimated)
Study Completion 2028-02-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-23